SWM
NBIX icon

SHP Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

SHP Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02K Sell
12
-3
-20% -$445 ﹤0.01% 1400
2026
Q1 		$1.98K Buy
15
+12
+400% +$1.59K ﹤0.01% 1280
2025
Q4 		$426 Buy
+3
New +$435 ﹤0.01% 1386

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SHP Wealth Management's NBIX Position: Q2 2026 in Review

SHP Wealth Management reduced its Neurocrine Biosciences (NBIX) stake by 20% in Q2 2026, selling an estimated $445 and leaving 12 shares worth $2.02K. The position accounts for ﹤0.01% of the portfolio, ranked #1400.

SHP Wealth Management first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • SHP Wealth Management held 12 shares of Neurocrine Biosciences worth $2.02K as of Q2 2026.
  • SHP Wealth Management sold 3 Neurocrine Biosciences shares in Q2 2026, an estimated $445.
  • Neurocrine Biosciences made up ﹤0.01% of SHP Wealth Management's portfolio in Q2 2026, its #1400 holding.
  • SHP Wealth Management first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.